Solid Biosciences Touts Encouraging Preclinical Data From Potential Duchenne Gene Therapy

• Solid Biosciences Inc (NASDAQ: SLDB) presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved transduction efficiency and biodistribution to muscle cells.

• In studies in wild-type mice, the mdx mouse model of Duchenne (DMDmdx) and non-human primates (NHPs) AAV-SLB101 demonstrated superior transduction efficiency compared with AAV9.

• In DMDmdx mice, the biodistribution of AAV-SLB101 to the quadriceps was significantly increased, and biodistribution to the liver and brain was decreased compared with AAV9.

• Related: Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%.

• In DMDmdx mice, microdystrophin protein expression was significantly higher with AAV-SLB101 than with AAV9.

• Across multiple mouse studies, muscle tissues treated with SGT-003 showed approximately 2- to 3-fold higher levels of microdystrophin protein.

• The company says the AAV-SLB101 capsid may be a superior candidate for muscle-targeted gene therapies, with the potential to achieve higher levels of efficacy with lower total doses.

• The company expects to submit an investigational new drug application (IND) for SGT-003 in mid-2023 and, subject to IND clearance, initiate patient dosing in late 2023.

• Price Action: SLDB shares are down 1.38% at $0.45 on the last check Monday.

See more from Benzinga

• FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug

• Moderna Inks Deal For Updated COVID Shots For Low Income Countries

• Elon Musk Warns Russia Can Utterly Destroy US, Europe With Nuclear Missiles In Under 30 Minutes And Vice

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.